TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05384756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo TMLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Medication to prevent the development of graft-versus-host disease (GVHD)
Study: NCT05414682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIND+SOUL Diet
Description: The MIND+SOUL Diet is an adapted brain-healthy soul food diet.
Study: NCT05823376

Intervention type: DRUG
Intervention: Avatrombopag
Description: Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10\^9/L; Drug administration will be stopped when PLT≥100×10\^9/L.
Study: NCT06481410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue Intervention Group
Description: In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Control Group
Description: In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
Study: NCT06464718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fortibone
Description: Participants were given daily sachet containing 5g of Bio active collagen peptides (Fortibone). Electrolyte mix containing 500 mg calcium as calcium lactate, 4 MCg calcitriol and selenised yeast rich in vitamin D3 (400IU) (Colabone®, Vivapharm SA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chewable Tablet
Description: calcium compound containing 25 g calcium carbonate (500mg elemental calcium) and vitamin D3 400IU taken daily
Study: NCT05517668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of N-acetylcysteine
Description: If randomized to Control, the participant will receive only N-acetylcysteine. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr. The control drug (D5W) will be administered using the same schedule as fomepizole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion of N-acetylcysteine
Description: If randomized to Control, the participant will receive only N-acetylcysteine. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr. The control drug (D5W) will be administered using the same schedule as fomepizole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of Fomepizole (4-MP)
Description: If randomized to fomepizole, the proposed infusion schedule for fomepizole closely mirrors the dosing outlined in the medication's package insert. Specifically, the Antizol (fomepizole) doses (bags) #1-5 allocated for the study will precisely adhere to the manufacturer's recommendations from the package insert. This entails an initial loading dose of 15 mg/kg followed by four subsequent doses of 10 mg/kg. The dose of fomepizole will not be adjusted based on age, presence of liver injury or renal insufficiency.
Study: NCT05312463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongjiang granule
Description: Tongjiang granules, 1 bag / time, 3 times / day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tongjiang granule simulant
Description: Tongjiang granule simulant,1 bag / time, 3 times / day.
Study: NCT04707469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
Study: NCT05581784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: PNE sessions will be led by an experienced physical therapist certified in PNE in 35-minute face-to-face group sessions. Here elements of the neurophysiology of pain are addressed, as well as the different psychosocial dimensions that influence it. The distribution of themes will be carried out as follows:~Week One: Coping with Pain. Week 2: Pain and Cognition Week 3: Your security system Week 4: Altered Alarm System (extra sensitive). Week 5: The defense system is in distress. Week 6: Fatigue, anxiety, and stress Week 7: Current Models of Treatment Week 8: Achievements and goals Week 9: Pain emphasis and differentiation This group remains with pharmacological treatment and the usual guidelines given by the doctor.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional management or Usual care
Description: This group will only have pharmacological treatment and the usual guidelines given by the doctor. Without educational intervention.
Study: NCT06202105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Gastrectomy with laparoscopic approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastrectomy
Description: Gastrectomy with laparoscopic approach
Study: NCT05920369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-energy extracorporeal shockwave and a tailored exercise program
Description: the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.~Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-energy extracorporeal shockwave
Description: the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-energy extracorporeal shockwave
Description: the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tailored exercise program
Description: Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tailored exercise program
Description: Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises
Study: NCT04146714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Substance use questionnaire
Description: Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity questionnaire
Description: Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
Study: NCT05897476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
Study: NCT06037460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Description: * 1 injection/2 weeks from W0 to W12: W0, W2, W4, W6, W8, W10, W12~* Then 1 injection/4 weeks until W24: W16, W20, W24

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: HAQ, SF-36, FACIT-Fatigue score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: HAQ, SF-36, FACIT-Fatigue score

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Additionnal blood samples for immunomonitoring

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Additionnal blood samples for immunomonitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18FDG PET scan
Description: PETVAS calculation (to be performed between W0 and W8) (optional).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 18FDG PET scan
Description: PETVAS calculation (to be performed between W0 and W8) (optional).
Study: NCT06137807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TricValve® Transcatheter Bicaval Valve System
Description: The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.
Study: NCT05453500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT01324986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic anti-reflux surgery
Study: NCT05453500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample and cerebrospinal fluid collection
Study: NCT06476392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 MG
Description: 2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
Study: NCT04608318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Cycles 1 - X: 420 mg daily, d1-28 p.o.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Cycles 1 - X: 420 mg daily, d1-28 p.o.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
Study: NCT05012163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Letter, short message service (SMS) text, phone, and/or email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Letter, short message service (SMS) text, phone, and/or email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Letter, short message service (SMS) text, phone, and/or email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Letter, SMS, phone, and/or email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Letter, SMS, phone, and/or email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery
Description: Letter, SMS, phone, and/or email
Study: NCT06199089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313 Injection
Description: Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Intravenous Placebo administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to placebo comparator group were treated with placebo of CM313 once a week for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of placebo of CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after placebo administration.
Study: NCT05317234

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing
Description: The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
Study: NCT05258162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Mobilisations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~  3 days per week for 3 weeks. Oscillations for 2 minutes at 2-3 oscillations per second.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.~  3 days per week for 3 weeks.
Study: NCT06470321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexiquit Computerized Smoking Cessation Program
Description: Flexiquit is an avatar-led, self-directed computerized program delivering evidence-based techniques to assist with smoking cessation. It includes motivational interviewing, psychoeducation on nicotine addiction, cognitive-behavioral strategies for coping with cravings, relapse prevention, and stress/emotion regulation skills training. Participants receive the program over 6 months and their adherence is monitored. The program provides tailored feedback to support abstinence.
Study: NCT05916768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelargonium sidoides extract EPs® 7630
Description: Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: symptomatic treatments
Study: NCT05046353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: Auditory remediation +/-D-serine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Auditory remediation +/-D-serine
Study: NCT05176808

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Achievements- Parent Coaching Intervention
Description: Children, along with a caregiver, will be randomized into one of two conditions to receive parent coaching guided by NDBI principles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Achievements- Parent Coaching Intervention
Description: Children, along with a caregiver, will be randomized into one of two conditions to receive parent coaching guided by NDBI principles.
Study: NCT04801550

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Millimeter waves local exposure
Description: several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Millimeter waves local exposure
Description: several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
Study: NCT04364958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A web based-Patient Decision Aid (PtDA) (shown on the computer)
Description: Patient decision aids (PtDAs) are tools that assist patients in making health decisions, when there is uncertainty about treatment choice, incorporating their personal preferences and values about the available treatment options. This PtDA will include information about GAD symptoms, diagnosis, causes, and benefits and risks associated to psychological and pharmacological treatments for GAD (based on the Clinical Practice Guidelines-GAD). It will also include a values clarification exercise, in which patients will have to rate the importance attributed to the different aspects of treatments (e.g., mode of administration, benefits, risks, time to improvement, probability of relapse).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.
Description: Patients in the control group will receive a fact sheet (one page) with general information on mental health as a part of usual care provided by the Canary Islands Health Service.
Study: NCT06217666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCX-12
Description: treatment combining radiation therapy with PCX12